Temozolomide for neuroendocrine tumors

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 14 Jan 2022: Trial started, NCT05554003
  2. 26 Sep 2022: Trial registered, NCT05554003

The trials

NCT05554003: Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

State
Under way
Phase
Phase 2
People
46 planned
Started
14 Jan 2022
Primary completion
31 Dec 2024
Arms
Metronomic Temozolomide
Results
None posted
  1. 14 Jan 2022: Trial started
  2. 26 Sep 2022: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Also known as Temodal, Temodar.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.